Published in Mol Cancer Res on November 17, 2015
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Molecular portraits of human breast tumours. Nature (2000) 94.14
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
Reproductive factors and breast cancer. Epidemiol Rev (1993) 8.37
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev (1995) 7.16
PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet (1999) 6.18
Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem (1999) 5.66
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J (1990) 5.05
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol (2000) 3.42
Regulation of transcriptional activation domain function by ubiquitin. Science (2001) 3.36
Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A (2003) 3.30
A flexible R package for nonnegative matrix factorization. BMC Bioinformatics (2010) 3.28
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol (1993) 2.89
Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A (2000) 2.69
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J (1998) 2.58
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras. J Biol Chem (2005) 2.46
Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell (2001) 2.44
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, cancer, and immune defense. Endocr Rev (2008) 2.06
The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem (2009) 2.05
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2014) 1.99
Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem (1998) 1.83
Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol (1993) 1.78
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol (2006) 1.64
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A (1998) 1.64
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol (1997) 1.62
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol (2005) 1.56
New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res (1994) 1.55
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle (2012) 1.54
Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem (2001) 1.48
Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol (2001) 1.46
Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem (2007) 1.43
Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol (2005) 1.41
Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol (2000) 1.39
Discovery of novel forkhead box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol (2010) 1.38
Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev (2010) 1.37
Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol (2007) 1.36
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep (2007) 1.34
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol (2004) 1.32
WISP-1 binds to decorin and biglycan. J Biol Chem (2001) 1.32
A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol (1992) 1.31
Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol (2003) 1.31
Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst (2002) 1.29
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol (2005) 1.25
Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol (2004) 1.24
Role of FOXO1A in the regulation of insulin-like growth factor-binding protein-1 in human endometrial cells: interaction with progesterone receptor. Biol Reprod (2005) 1.22
Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells. Mol Endocrinol (1988) 1.21
Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer (2013) 1.20
Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer (2000) 1.13
Differential localization and activity of the A- and B-forms of the human progesterone receptor using green fluorescent protein chimeras. Mol Endocrinol (1999) 1.12
Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology (2005) 1.11
Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One (2012) 1.09
New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem (2002) 1.08
Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res (2012) 1.08
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal (2009) 1.08
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia (2011) 1.07
Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle (2013) 1.07
Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol (1999) 1.06
Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids (2005) 1.04
Differential expression of progesterone receptor isoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res (2002) 1.01
Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res (2012) 1.00
ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol (2011) 1.00
Progesterone receptor and Stat5 signaling cross talk through RANKL in mammary epithelial cells. Mol Endocrinol (2013) 1.00
Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res (1996) 0.99
Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene (2014) 0.98
Progesterone action in breast, uterine, and ovarian cancers. J Mol Endocrinol (2015) 0.98
Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer (2009) 0.98
Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol (2009) 0.98
Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathology (2011) 0.96
Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer (2012) 0.94
Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol (2009) 0.93
Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol (2001) 0.92
Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res (2013) 0.90
Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res (2007) 0.89
Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity. J Mol Endocrinol (2007) 0.88
Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer (2000) 0.88
Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem (1996) 0.88
Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. J Biol Chem (2009) 0.87
Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis. Horm Cancer (2011) 0.86
The epidemiology of ovarian cancer. Int J Gynecol Cancer (2002) 0.86
A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res (2013) 0.85
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol (1998) 0.84
Regulation of Ras localization and cell transformation by evolutionarily conserved palmitoyltransferases. Mol Cell Biol (2013) 0.84
Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol (2014) 0.82